CATALYST PHARMACEUTICALS, INC.: 10-K filed 2015-03-13

Name: CATALYST PHARMACEUTICALS, INC.: 10-K filed 2015-03-13
Creator: CATALYST PHARMACEUTICALS, INC.

What CATALYST PHARMACEUTICALS, INC. reported in its annual report filed 2015-03-13 (fiscal FY 2014): 28 published measures, 96 facts as tagged in accession 0001193125-15-091323.

This filing

Form: 10-K (annual report)
Filed: 2015-03-13
Fiscal period: fiscal FY 2014
Accession: 0001193125-15-091323 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CATALYST PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2014-12-31	43,908,086	USD
At 2013-12-31	25,369,554	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2014-12-31	8,665,756	USD
At 2013-12-31	3,978,302	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2014-12-31	35,242,330	USD
At 2013-12-31	21,391,252	USD
At 2012-12-31	14,622,115	USD
At 2011-12-31	3,760,698	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2014-12-31	9,096,778	USD
At 2013-12-31	2,215,958	USD
At 2012-12-31	1,409,939	USD
At 2011-12-31	6,029,067	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	-3,490,030	USD	92
2014-01-01 to 2014-12-31	-15,509,061	USD	365
2014-07-01 to 2014-09-30	-5,009,892	USD	92
2014-04-01 to 2014-06-30	-3,198,020	USD	91
2014-01-01 to 2014-03-31	-3,811,119	USD	90
2013-10-01 to 2013-12-31	-1,354,658	USD	92
2013-01-01 to 2013-12-31	-12,154,596	USD	365
2013-07-01 to 2013-09-30	-5,912,059	USD	92
2013-04-01 to 2013-06-30	-3,143,590	USD	91
2013-01-01 to 2013-03-31	-1,744,289	USD	90
2012-01-01 to 2012-12-31	-4,076,386	USD	366

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	57,323	USD	365
2013-01-01 to 2013-12-31	9,432	USD	365
2012-01-01 to 2012-12-31	52,382	USD	366

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Unit	Days
2014-10-01 to 2014-12-31	USD	92
2014-01-01 to 2014-12-31	USD	365
2014-07-01 to 2014-09-30	USD	92
2014-04-01 to 2014-06-30	USD	91
2014-01-01 to 2014-03-31	USD	90
2013-10-01 to 2013-12-31	USD	92
2013-01-01 to 2013-12-31	USD	365
2013-07-01 to 2013-09-30	USD	92
2013-04-01 to 2013-06-30	USD	91
2013-01-01 to 2013-03-31	USD	90
2012-01-01 to 2012-12-31	USD	366

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2014-12-31	-69,842,660	USD
At 2013-12-31	-54,333,599	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Unit	Days
2014-01-01 to 2014-12-31	USD	365
2013-01-01 to 2013-12-31	USD	365
2012-01-01 to 2012-12-31	USD	366

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2014-12-31	71,377	USD
At 2013-12-31	40,628	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	777,969	USD	365
2013-01-01 to 2013-12-31	175,855	USD	365
2012-01-01 to 2012-12-31	340,039	USD	366

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	-3,983,861	USD	92
2014-01-01 to 2014-12-31	-14,591,428	USD	365
2014-07-01 to 2014-09-30	-4,109,029	USD	92
2014-04-01 to 2014-06-30	-2,990,173	USD	91
2014-01-01 to 2014-03-31	-3,508,365	USD	90
2013-10-01 to 2013-12-31	-2,706,923	USD	92
2013-01-01 to 2013-12-31	-10,311,658	USD	365
2013-07-01 to 2013-09-30	-3,245,776	USD	92
2013-04-01 to 2013-06-30	-2,653,529	USD	91
2013-01-01 to 2013-03-31	-1,705,430	USD	90
2012-01-01 to 2012-12-31	-5,221,140	USD	366

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2014-12-31	43,827,821	USD
At 2013-12-31	25,320,038	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2014-12-31	5,855,026	USD
At 2013-12-31	2,139,609	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2014-12-31	1,814,210	USD
At 2013-12-31	850,789	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	14,591,428	USD	365
2013-01-01 to 2013-12-31	10,311,658	USD	365
2012-01-01 to 2012-12-31	5,221,140	USD	366

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	10,117,774	USD	365
2013-01-01 to 2013-12-31	8,096,774	USD	365
2012-01-01 to 2012-12-31	2,659,597	USD	366

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2014-12-31	69,119,092	shares
At 2013-12-31	54,132,937	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2014-12-31	105,015,871	USD
At 2013-12-31	75,670,718	USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2014-12-31	184,570	USD
At 2013-12-31	133,074	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2014-12-31	113,193	USD
At 2013-12-31	92,446	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2014-12-31	4,040,816	USD
At 2013-12-31	1,288,820	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2014-12-31	4,552,698	USD
At 2013-12-31	1,609,442	USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

Period	Value	Unit	Days
At 2014-12-31	24,895,000	USD
At 2013-12-31	19,387,000	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	4,473,654	USD	365
2013-01-01 to 2013-12-31	2,214,884	USD	365
2012-01-01 to 2012-12-31	2,561,543	USD	366

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	26,574	USD	365
2013-01-01 to 2013-12-31	22,483	USD	365
2012-01-01 to 2012-12-31	10,889	USD	366

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	76,233	USD	365
2013-01-01 to 2013-12-31	47,421	USD	365
2012-01-01 to 2012-12-31	14,976	USD	366

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	963,421	USD	365
2013-01-01 to 2013-12-31	-514,874	USD	365
2012-01-01 to 2012-12-31	1,101,729	USD	366

Inspect the source

Entity: CATALYST PHARMACEUTICALS, INC. / CIK 0001369568
Captured: 2026-09-21T17:19:25.463Z
SEC response SHA-256: 7cf76a511a9127dd31ed7d53955bbe348f790d8d7fd354d359e6674e7b2af9c9

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001369568.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))